资讯

Pharmaceutical Technology2 天
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).
TMCnet3 天
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE ...
Dyne anticipates filing a Biologics License Application (BLA) submission for US accelerated approval in early 2026.